Skip to main content
. 2021 Jan 7;56(6):1341–1351. doi: 10.1038/s41409-020-01187-5

Table 4.

Prognostic factors of patients with GIB after haplo-HSCT.

Variables Patients (n, %) Univariate P value Multivariate
Death (−) Death(+) HR 95% P value
Age > 30 54 (44.3) 37 (56.1) 0.045 1.427 0.833–2.444 0.195
Male 68 (55.7) 43 (65.2) 0.296
Transplant complications prior to GIB
 III–IV aGVHD 60 (49.2) 44 (66.7) 0.004 2.302 1.340–3.952 0.003
 Extensive cGVHD 11 (9.0) 6 (9.1) 0.566
 TMA 2 (1.6) 11 (16.7) 0.000 5.539 2.745–11.179 0.000
 SOS 0.120
 DIC 1 (0.8) 7 (10.6) 0.000 4.535 1.963–10.478 0.000
 AKI 16 (13.1) 22 (33.3) 0.000 2.621 1.510–4.548 0.001
 Intestinal infection 41 (33.6) 21 (31.8) 0.934
 CMV viremia 67 (54.9) 45 (68.2) 0.087 1.306 0.749–2.277 0.346
 Gastrointestinal disease or bleeding before HSCT 7 (5.7) 12 (18.2) 0.002 3.748 1.925–7.296 0.000
Laboratory data at the occurrence of GIB
 Hb < 80 g/L 59 (48.4) 38 (57.6) 0.056 1.319 0.785–2.215 0.296
 Platelet count < 30 × 109/L 58 (47.5) 34 (51.5) 0.421
 Platelet count < 20 × 109/L 33 (27.0) 26 (39.4) 0.083 1.390 0.802–2.410 0.241
Comorbidities
 Viral hepatitis 14 (11.5) 8 (12.1) 0.659
 Hypertension 9 (7.4) 11 (16.7) 0.109
 Diabetes mellitus 5 (4.1) 5 (7.6) 0.422
 Alcohol 4 (3.3) 2 (3.0) 0.997

GIB gastrointestinal bleeding, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, SOS sinusoidal obstruction syndrome, TMA thrombotic microangiopathy, DIC disseminated intravascular coagulation, AKI acute kidney injury, CMV cytomegalovirus, HSCT hematopoietic stem cell transplantation.